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Abstract
The secretion of angiogenic factors by vascular endothelial cells is one of the key mechanisms of angiogenesis. Here we
report on the isolation of a new potent angiogenic factor, diuridine tetraphosphate (Up4U) from the secretome of human
endothelial cells. The angiogenic effect of the endothelial secretome was partially reduced after incubation with alkaline
phosphatase and abolished in the presence of suramin. In one fraction, purified to homogeneity by reversed phase and
affinity chromatography, Up4U was identified by MALDI-LIFT-fragment-mass-spectrometry, enzymatic cleavage analysis and
retention-time comparison. Beside a strong angiogenic effect on the yolk sac membrane and the developing rat embryo
itself, Up4U increased the proliferation rate of endothelial cells and, in the presence of PDGF, of vascular smooth muscle
cells. Up4U stimulated the migration rate of endothelial cells via P2Y2-receptors, increased the ability of endothelial cells to
form capillary-like tubes and acts as a potent inducer of sprouting angiogenesis originating from gel-embedded EC
spheroids. Endothelial cells released Up4U after stimulation with shear stress. Mean total plasma Up4U concentrations of
healthy subjects (N = 6) were sufficient to induce angiogenic and proliferative effects (1.3460.26 nmol L-1). In conclusion,
Up4U is a novel strong human endothelium-derived angiogenic factor.
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Introduction
Vasculature in adult mammals is mainly quiescent; however,
new blood vessel formation is required for timely tissue repair and
remodeling after injury [1]. The formation of new blood vessels is
an essential process in the life of higher organisms. Development,
reproduction, wound healing, communication of humoral signals,
transport of nutrients and waste products all require angiogenesis
[2]. The process of angiogenesis involves migration, proliferation,
differentiation, and adhesion of multiple cell types, including
endothelial, mural, and inflammatory cells [3,4].
However, disease processes such as cancer growth [5], diabetic
retinopathy or chronic inflammation are also dependent on
angiogenesis [6]. Hence, the humoral mechanisms of angiogenesis
have attracted increasing interest [7]. Among those, interest has
focused on peptidic angiogenic factors such as the vascular
endothelial growth factors, hepatocyte growth factor or fibroblast
growth factor, and non-peptidic, low molecular angiogenic factors
such as adenosine or hypoxic metabolites, e. g. lactate or pyruvate,
which mediate hypoxia-induced angiogenesis. Although various
cell types are required in the humoral regulation of angiogenesis;
the contribution of vascular endothelial cells is probably the most
important. However, our knowledge about the mediators secreted
by endothelial cells inducing angiogenesis is just at the beginning.
Unravelling these mediators involved in angiogenesis would offer
therapeutic options to ameliorate disorders that are currently
leading causes of mortality and morbidity, including cardiovascu-
lar diseases, cancer, chronic inflammatory disorders, diabetic
retinopathy, excessive tissue defects, and chronic non-healing
wounds. The knowledge of the endogenous mediators involved
provides numerous opportunities for therapeutic intervention [8].
Therefore, we screened the secretome of human endothelial cell
cultures for further, yet unknown angiogenic factors by using the
culture of rat embryos including their yolk sac with its developing
vascular system. The embryos were cultured during organogen-
esis, when angiogenesis is a fundamental process [9,10]. The
whole embryo culture (WEC) has been used before to study
different growth factors, e.g. vascular endothelial growth [11], or
to demonstrate the impact of different genes involved in
angiogenesis [12]. We showed that incubation with alkaline
phosphatase just partly reduced and blockade of purine P2
receptors markedly reduced the angiogenic effect of the endothe-
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lial secretome. Subsequently, diuridine tetraphosphate (Up4U) was
identified as the responsible angiogenic factor.
Materials and Methods
Chemicals
HPLC water (gradient grade) and acetonitrile were purchased
from Merck (Germany), all other substances from Sigma Aldrich
(Germany).
Culture of Endothelial Cells
Human endothelial cells from dermal microvessels (HMEC-1)
present the first immortalized human microvascular endothelial
cell line that retains the morphologic, phenotypic, and functional
characteristics of normal human microvascular endothelial cells
[13]. These cells were cultured in MCDB 131 medium supple-
mented with 100 U ml-1 penicillin/streptomycin, 1% (v/v) L-
glutamine and 7.5% (v/v) fetal bovine serum. Experiments
comparing the phenotypic characteristics of HMEC-1 cells with
human dermal microvascular endothelial cells or human umbilical
vein endothelial cells revealed that HMEC-1 cells show features of
both, small- and large-vessel endothelial cells [13]. On day 0 cells
were placed into 175 cm2 cell-culture flasks (Nunc Inc., Germany)
and were stimulated on day 2 at approximately 70% confluency.
Confluent cultures of HMEC-1 cells showed typical cobblestone
appearance and were further characterized by the expression of
Willebrand factor, endothelial nitric oxide synthase, VEGF
receptor 1 (FLT-1) and absence of smooth muscle a-actin staining
[14]. Primary human umbilical vein endothelial cells (HUVEC)
were commercially obtained (Promocell, Germany) and expanded
with endothelial growth medium (Promocell, Germany). Experi-
ments were performed with cells grown for no more than four
passages.
Stimulation of Cultured Endothelial Cells
Cell-culture flasks of endothelial cells (n = 30) were washed three
times with a physiological salt solution. After addition of 15 ml
physiological salt solution, the cell-culture flasks of endothelial cells
were exposed to shear stress for 10 min by using a horizontally
shaking machine [15]. The supernatant was collected and pooled
after shear stress stimulation. Aliquots of the resulting supernatants
were incubated with immobilized alkaline phosphatase as
described earlier [16]. The supernatant was deproteinized with
perchloric acid (final concentration 0.6 mol L-1) and centrifuged
(3,500 U min-1; 4uC; 5 min). Perchloric acid was precipitated by
adding KOH (pH 9.5). The precipitated proteins and the
insoluble reaction product KClO4 were removed by centrifugation
(3,500 U min-1; 4uC; 5 min). Aliquots of the supernatant were
neutralized before testing in the bioassay. For control reactions, 30
cell-culture flasks of endothelial cells were washed three times with
15 ml of a physiological salt solution by avoiding mechanical
stress. Salt solution was added extremely slowly. After washing,
15 ml physiological salt solution was added to the endothelial cells.
10 min later, the supernatant was collected and pooled.
Application of Shear Stress by Cone-and-plate
Viscometer
Cultured human umbilical vein endothelial cells (HUVEC) were
subjected to shear stress in a cone-and-plate viscometer [17,18].
The secretome of HUVEC exposed to 1 dyn cm-2 (low, 0.1 N m-2)
and 30 dyn cm-2 (high, 3.0 N m-2) shear stress for 24 h were
compared to the secretome of static control cells (0 dyn cm-2). Cell
culture medium supplemented with 5% dextran T-70 (Sigma-
Aldrich, Germany) was added to the cell culture medium 1 h prior
to biomechanical stimulation to increase the viscosity 2.95-fold to
0.02065 dyn s-1 cm-2. Dextran had no influence on the expression
of genes studied.
Whole Embryo Culture (WEC)
This study was approved by the ‘‘Ethical Committee Charite´’’. All
animal procedures conducted were in accordance with the
guideline for the care and use of laboratory animals by the
‘‘Research Institute of Experimental Medicine’’ (FEM) of the Charite´
(Germany), approved by the ‘‘Ethical Committee Charite´’’. Wistar rats
unilever (Bor:isw/SPF, TNO; Harlan-Winkelmann, Germany)
were kept under specific pathogen-free conditions at a constant
day and night cycle of 12 hours starting at 9:00 a.m. and 9.00 p.m
and the following 24 h were designated as day 0 of pregnancy
when sperm was detected in the vaginal smear.
On gestational day 9.5, the gravid rats were sacrificed by
decapitation and the rat embryos were prepared and cultured
according to a method previously published in detail [19]. The
preparation of the embryos was performed in HBSS, they were
placed in groups of four into sealed culture flasks (50 ml)
containing 7 ml of the culture medium. The culture medium
consists of 15% HBSS and 85% donor bovine serum (Quad Five,
USA), supplemented with 1.57 mg ml-1 D-glucose (Merck
Eurolab, Germany) and 75 mg ml-1 L-methionine (Sigma-Aldrich,
Germany). For incubation the culture flasks were placed for 48 h
into a roller device (Memmert, Germany) at a speed of 25 rpm and
a temperature of 38.5uC. Initiating the culture, the flasks were
gassed with 10% O2, 5% CO2, and 85% N2. After 36 h the
oxygen concentration was raised to 50%.
After 48 h of culture the embryos were evaluated for their
growth (crown-rump length and protein content) and their
differentiation (number of somites and morphological score) [19]
using a dissection microscope. Finally the development of the yolk
sac was estimated with special attention to its blood vessels system.
After the morphological evaluation of the cultured embryos and
their corresponding yolk sacs these tissues have been frozen and
immediately stored at280uC.
Chromatographic Analysis of the Supernatants of
Endothelial Cells
Supernatants of stimulated endothelial cells were fractionated
by a series of reversed-phase and affinity chromatographic steps.
Triethylammonium acetate (40 mmol L-1 final concentration) was
added to the supernatants. pH was titrated to 6.5. Next, two C18
reversed-phase columns (Chromolith Performance, RP C18e,
10064.6 mm, Merck, Germany) connected in series were used to
concentrate the supernatant of stimulated and unstimulated
endothelial cells. Non-binding substances were removed with
triethylammonium acetate. Binding substances were eluted
stepwise with 25% acetonitrile (ACN), in water at a flow rate of
1.0 ml min-1. Unless specified the chromatographic eluent was
monitored at 254 nm using a (make and model of detector). The
eluate was retained and frozen at –80uC and lyophilised.
The eluate of the preparative reversed-phase chromatography
column was purified further with affinity chromatography. The
affinity chromatography gel, phenyl boronic acid coupled to a
cation exchange resin (Biorex 70, Bio-Rad, USA), was synthesized
according to Barnes et al.[20]. The affinity resin was packed into a
glass column and equilibrated with 0.3 mol L-1 ammonium acetate
(pH 9.5). The pH of the eluate from the preparative reversed-
phase chromatography was adjusted to pH 9.5 and loaded to the
affinity column. The column was washed with an ammonium
acetate solution with a flow rate of 1.0 ml min-1. Binding
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substances were eluted with 1 mmol L-1 HCl solution. The eluate
was retained and frozen at 220uC.
1 mol L-1 triethylammonium acetate was added to the eluate of
the affinity chromatography (final concentration: 40 mmol L-1).
The eluate of the affinity chromatography was injected into a
reversed phase high performance liquid chromatography (Chro-
molith RP-18e 100-4.6, Merck, Germany) for desalting. After
removal of substances not binding to the column with aqueous
40 mmol L-1 triethylammonium acetate, the absorbed substances
were eluted with 20% acetonitrile (ACN) in water at a flow rate of
1.0 ml min21. Each eluate was frozen at –80uC and lyophilized.
The lyophilised eluate was then dissolved in 40 mmol L-1
triethylammonium acetate (eluent A) and injected in two reversed
phase columns (Chromolith RP-18e 100-4.6 Merck, Germany)
connected in series. 80% acetonitrile (eluent B) and the following
gradient were used for the elution: 0–10% B 40 min, 10–100% B
1 min, 100% B 2 min. The flow rate was 1.0 ml min-1 and 1 ml
fractions were collected.
Determination of Recovery Rates
To calculate the recovery rate for Up4U, in a control
experiment, either culture medium or plasma (40 ml) was spiked
with Up4U (5 mg). These samples were fractionated as described
above.
Matrix Assisted Laser Desorption/Ionisation Mass
Spectrometry (Maldi-MS)
The lyophilised fractions of the reverse-phase chromatography
were analysed by matrix-assisted laser desorption/ionisation mass
spectrometry (MALDI-MS) and MALDI fragment ion analysis
using a Bruker Ultraflex TOF/TOF instrument (Bruker-Dal-
tonics, Germany). The concentrations of the analysed substances
were 1–10 mmol L–1 in double distilled water. 1 ml of the analyte
solution was mixed with 1 ml of matrix solution (50 mg ml–1 3-
hydroxy-picolinic acid in water). Cation exchange beads (AG
50 W-X12, 200–400 mesh, Bio-Rad, Germany) were added to this
mixture and equilibrated with NH4
+ as a counter-ion to remove
Na+ and K+ ions. 1 ml of each fraction was prepared on a
prestructured MALDI sample support (MTP AnchorChipTM
400/384, Bruker-Daltonics, Germany) [21] and dried gently on
an inert metal surface before introduction into the mass
spectrometer.
Mass-spectrometric measurements were performed on a Bruker
Ultraflex-III TOF/TOF instrument (Bruker-Daltonics, Germany).
The instrument was equipped with a Smart beamTM laser
operating with a repetition-rate of 100–200 Hz. On average, the
presented spectra are the sums of 300 single-shot spectra for MS
mode, and 1,000 for MS/MS mode. Argon was used as collision-
induced dissociation (CID) gas. Mass spectra of positively charged
ions were analysed in the reflector mode using delayed ion
extraction. Fragment ion spectra were recorded using the LIFT
option of the instrument. The calibration constants were
determined using standard peptides prepared on positions
adjacent to the sample, resulting in an error of ,50 ppm for the
recorded mass spectra. The dinucleoside polyphosphate ApcpcpA
was added to the sample as internal standard in the case of kinetic
measurements by using MALDI mass spectrometry. Local
differences in the Up4U-concentration on the MALDI spot were
thereby eliminated [22].
Enzymatic Cleavage Experiments
Enzymatic cleavage experiments were performed as described
elsewhere [16,23]. Briefly, 5-nucleotide hydrolase (3 mU) from
Crotalus durissus (Sigma-Aldrich, Germany), 3`-nucleotide hydro-
lase (1 mU) from calf spleen (Sigma-Aldrich, Germany) and
alkaline phosphatase (1 mU) from calf intestinal mucosa (Fluka,
Germany), respectively were mixed with 50 ml NaHCO3 and
activated CNBr-Sepharose 6 MB beads (Amersham-Pharmacia
Biotech, Sweden). The mixture was incubated for 2 hours at room
temperature. After incubation, the beads were washed 3 times with
double distilled water. Aliquots of the fractions from the reversed
phase chromatography were incubated with these enzyme-beads
for 2 hours at room temperature. Aliquots of the reaction mixture
were examined by MALDI-MS. 40–50 single spectra were
accumulated to improve the signal-to-noise ratio [23]. Sample
preparation and measurements were done at the same conditions
as for the original samples.
Synthesis of Diuridine (59, 59) Tetraphosphate
Up4U was synthesized according to Ng and Orgel [24]. Uridine
59-diphosphate (UDP; 50 mmol L-1), (N-[2-hydroxyethyl]-pipera-
zine-N-[2-ethanesulfonic acid]) (HEPES; 2 mol L-1, 1-ethyl-3-(3-
dimethylamino-propyl)carbodiimide (2.5 mol L-1) and magnesium
chloride (MgCl2; 125 mmol L
-1) were dissolved in water,
thoroughly mixed with a vortex mixer and incubated at 37uC at
pH 6.5 for 48 h. Purification of chemically synthesized dinucleo-
side (59,59) polyphosphates was performed as described elsewhere
[25]. Briefly, the synthesized dinucleoside polyphosphates were
concentrated on a C18 reversed phase column (LiChroprep,
310625 mm, 65-40 mm, Merck, Darmstadt, Germany) using
40 mmol L-1 aqueous triethylammonium acetate (TEAA) in water
(eluent A; flow rate: 2.5 ml min-1). After removing non-binding
substances with eluent A (flow rate: 2.5 ml min-1), nucleotides were
eluted with 36% acetonitrile in water (eluent B; flow rate: 2 ml
min-1). The eluate was lyophilized and stored frozen at280uC.
The lyophilized eluate of the preparative reversed phase chroma-
tography was dissolved in aqueous 40 mmol L-1 triethylammo-
nium acetate solution and injected on two C18 reversed phase
columns connected in series (Supersphere, 30068 mm, 4 mm,
Merck, Germany) which were equilibrated with aqueous 40 mmol
L-1 triethylammonium acetate (carrier). The carrier was pumped
through the system with a flow rate of 100 ml min-1 during
injection of the sample. After the injection was finished, n-butanol
(160 mmol L-1) in 40 mmol L-1 triethylammonium acetate was
used as displacer (flow rate: 200 ml min-1). The fraction size was
1.9 ml. Each fraction of the displacement-chromatography possi-
bly containing dinucleoside polyphosphates was lyophilized,
dissolved in 1 ml 20 mmol L-1 K2HPO4 in water, pH 8, (eluent
A) and chromatographed by using an anion-exchanger (column:
UNO Q-12, BioRad, Germany)(eluent B: 20 mmol L-1 K2HPO4
and 1 mol L-1 salt (pH 8) in water; gradient: 0–10 min: 0–5% B;
10–10 min: 5–35% B; 100–101 min: 35–100% B; flow rate:
3.0 ml min-1; UV absorption wavelength: 254 nm). The fractions
of the anion-exchange chromatography were desalted by HPLC
reversed phase C18 chromatography. The reversed phase column
(ChromolithTM Performance RP-18e100-4.6, Merck, Germany)
was equilibrated with eluent A (40 mmol L-1 triethylammonium
acetate). Each sample dissolved in 40 mmol L-1 triethylammonium
acetate was pumped with a flow rate of 1.0 ml min-1 onto the
column. After 20 minutes washing the column with 30 ml eluent
A, the substances were eluted with 32% acetonitrile in water
(eluent B). The resulting fractions were lyophilized and stored at
280uC. The lyophilized fractions from the HPLC reversed phase
C18 chromatography were examined by MALDI-MS.
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Isolation and Identification of Diuridine Tetraphosphate
in Human Plasma
The blood collection was approved by the ethical committee of
the Charite´. The probands gave their written consent. Peripheral
blood (20 ml) was drawn from the cubital vein in six healthy
subjects and was collected in tubes containing K2-EDTA (7.2 mg).
The mean age of the subjects (m/f: 3/3) was 31.862.8, systolic
blood pressure 11862 (mmHg), diastolic blood pressure 7363
(mmHg)(each mean 6 SEM). The blood samples were centrifuged
at 2,100 g for 10 min at 4uC for isolation of plasma, after a
standardized interval of 15 min post sampling. 5 mg of a diinosine
tetraphosphate (Ip4I) was added as internal standard and used to
compensate for any losses during purification. The plasma was
deproteinized with 0.6 mol L-1 (final concentration) perchloric
acid and centrifuged (2,100 g, 4uC, 5 min). After adjusting pH to
7.0 with 5 mol L-1 KOH the precipitated proteins and KClO4
were removed by centrifugation (2,100 g, 4uC, 5 min).
Isolation and Identification of Diuridine Tetraphosphate
from Human Plasma
Triethylammonium acetate (TEAA) in water was added to the
deproteinized plasma to a final concentration of 40 mmol L-1.
This mixture was fractionated to homogeneity by reversed phase
chromatographic and affinity chromatographic methods compa-
rable to the methods used for the chromatographic analysis of the
endothelial secretome. Up4U was identified on the basis of its
retention time as compared to synthetic Up4U. The lyophilised
fractions from the reverse phase HPLC with TEAA as the ion-pair
reagent were further separated by analytic reverse phase HPLC
using tetrabutylammonium hydrogensulfate (TBA) as the ion-pair
reagent. The fractions, dissolved in 150 ml of 2 mmol L-1 TBA and
10 mmol L-1 K2HPO4 (pH 6.5), were injected into a reverse phase
HPLC column (ChromolithTMPerformance, RP-18e; 100-
4.6 mm; Merck, Germany). Acetonitrile (80% (v/v) in water:
eluent B) and the following gradient was used for the elution: 0–
41 min: 0–30% eluent B; 41–41.5 min: 30–100% eluent B; 41.5–
44.5 min: 100% eluent B; flow: 3 ml min-1. The concentrations of
Up4U were calculated using calibration curves created with
synthetic Up4U.
Detection of Endothelial Cell Proliferation
To detect cell proliferation after treatment with Up4U,
HUVECs were incubated in the presence of 10 mmol L-1 of the
thymidine analogue 59bromo-29deoxyuridine, following the man-
ufacturer’s protocol (BrdU, Roche, Germany). Briefly, HUVEC
were seeded into 96 well plates at a cell density of 2,000 cells well-1.
Cells were treated with increasing concentrations of Up4U (0, 0.1,
1, 10, 100 nmol L-1) in endothelial cell growth medium containing
0.1% FBS for 24 h. To inhibit the Up4U effect, cells were treated
with 100 mmol L-1 suramin (Sigma-Aldrich, Germany) in the
presence of Up4U. Cells were labelled with 10 mmol L
-1 BrdU in
the last 4 h of treatment. After fixation, cells were incubated with
Blocking Reagent (Roche, Germany) for 30 min to reduce
unspecific binding of the antibody conjugate. Incorporated BrdU
was detected with monoclonal anti-BrdU-POD antibody (30 min
at RT) and ABST substrate (15–30 min at RT). Absorbance was
measured at 370 nm (reference 492 nm). The experiment was
carried out with 6 wells for each treatment and was repeated three
times.
Migration Assays
Migration assays were performed using a disposable 96-well
ChemoTX chamber (Neuro Probe, USA) with 8 mm pores. Prior
to each experiment filters were coated with 0.1 mg ml-1 collagen
type I and placed at 37uC for 1 h to polymerize. For each
experiment quiescent cells were loaded with 1 mmol L-1 Calcein-
AM (Invitrogen, USA) in DMEM containing 0% FCS and
1.25 mmol L-1 probenecid for 1 h to enable a fluorescent
detection of the cells. After loading with the dye cells were
harvested with trypsin and resuspended in DMEM containing 0%
FCS and 1.25 mmol L-1 Probenecid. The lower wells of the plate
were filled with test substances, covered with the filter and 2.56104
cells were placed on the filter sites. The chamber was incubated for
5 h at 37uC and 5% CO2. Following incubation, non-migrated
cells were mechanically removed and the filter was measured using
the fluorescence signal of calcein at 485 nm (excitation) and
535 nm (emission) in a fluorescence plate reader (Mithras LB 940,
Berthold Technologies, Germany).
Detection of Vascular Smooth Muscle Cell Proliferation
Proliferation was determined by bromodeoxyuridine (BrdU)
incorporation during DNA synthesis, using a BrdU-ELISA (Roche
Diagnostics, Switzerland). Cells were plated at a density of 2,500
cells well-1 in 96-well plates and cultured for 24 h. Following 24 h
in serum-reduced medium (0.5% FCS), the culture medium was
removed and fresh medium containing the test substances was
added to the growth-arrested cells for another 24 h. BrdU was
offered in the last 4 h of the incubation time. After stimulation cells
were fixed, incubated with anti-BrdU-POD antibody and washed
according to manufacturer`s instructions. Substrate solution was
added to the wells and the luminescence signal representing the
BrdU incorporation was recorded immediately by a luminescence
plate reader (Mithras LB 940, Berthold Technologies, Germany).
Tube Formation
The tube formation assay was carried out with the m-slide
angiogenesis system from Ibidi (Integrated BioDiagnostics, Ger-
many). The m-slides were coated with growth-factor reduced BD
Matrigel (BD Biosciences, Japan) and placed at 37uC for 1 h to
polymerize. HMECs were harvested and resuspended in growth
factor free MCDB 131 medium at a density of 26105 cells ml-1.
From this solution 50 ml were applied in each ml-slide well and
incubated for 6 h. Tube formation was measured using micro-
scopic images of five different areas. Tubular length and total
number of tubes were quantified.
Sheroid Sprouting Assay
HUVEC cells were cultured in endothelial cell culture medium
consisting of endothelial basal cell growth medium containing
(ECM2), 2% FBS and endothelial cell growth supplements. The
cells were cultured to 90% confluency at 37uC and 5% CO2 and
used from passage 2 to passage 4. Endothelial spheroids were
generated as described previously [26]. Briefly, human umbilical
vein endothelial cells (2,500–3,000 cells per spheroid) were
resuspended in endothelial cell culture medium containing 20%
carboxymethylcellulose and plated in nonadherent round-bottom
96-well plates for 24 hours allowing single spheroid aggregation.
Spheroids were harvested and combined in a 1.5 ml Eppendorf
tube. Cell culture supernatant was removed after centrifugation for
1 min at 500 x g. 30 spheroids were embedded into 120 ml
collagen gels in 24-well plates [27]. For collagen stock solution,
8 vol rat tail collagen type I (Collaborative Medical Products, US)
was mixed with 1 vol. 10x PBS (Sigma-Aldrich, Germany) and
1 vol. 0.1 N NaOH to adjust to pH 7.4 at room temperature.
This stock solution was then mixed with an equal volume of
endothelial basal growth medium (ECM2, Lonza, Germany)
containing 40% FBS (Lonza, Germany) and 0.5% carboxymeth-
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ylcellulose to prevent spheroid sedimentation during collagen gel
polymerization. Spheroid containing gels were allowed to poly-
merize for 20 min at 37uC and 5% CO2 and then overlaid with
endothelial cell culture medium (ECM), supplemented with Up4U
concentrations as indicated or 20 ng ml-1 VEGF (Sigma-Aldrich,
Germany). After 24 hours in vitro sprout formation was evaluated
in phase-contrast images (Leica, Germany) and quantified by
SCORE image analysis (SCO Life Science, Germany).
Phosphoprotein Detection for Map-Kinases
Serum-starved VSMCs were stimulated with Up4U for the
indicated time points. After harvesting cells with ice-cold cell lysis
buffer (Biorad, Munich, Germany), centrifuged for 20 min at 4uC
and 13.000 rpm, supernatant was spiked with equal amount of
assay buffer (Biorad, Munich, Germany). Protein amount of the
lysates was determined with BCATM assay kit (Pierce, Rockford,
USA). Determination of phosphorylated as well as total protein
was assayed using LuminexTM technology with the phospho-
protein detection assay (Biorad, Munich, Germany).
In-Vivo/Ex-Vivo Assay of Up4U Production in Isolated
Aortic Rings
Thoracic and abdominal aorta was isolated from Wistar rats
(n = 4). The surrounding fat tissue was removed and aortas were
serially cross-sectioned into 1–2 mm rings. A total of 10–15 aortic
rings were seeded into a 12-well plate and serum-starved in Opti-
MEM for 24h to equilibrate their growth factor responses. Then
the conditioned medium was collected (base-line) and fresh serum-
free medium was added in the absence (Control) or presence of
calcium ionophore (10 mmol L-1, Sigma) or endothelin 1 (0.1 nmol
L-1, Sigma). Conditioned media was collected after 45 minutes,
deproteinated and frozen until assayed.
Statistical Methods
Data are given as mean values with standard error mean (SEM).
All statistical analyses were done using SPSS software (Microsoft
SPSS for Windows, version 12.0). The Wilcoxon-Mann-Whitney
test was used for non-parametric statistical tests. p,0.05 (two-
sided) was considered to indicate statistical significance.
Results
The screening approach using the chorioallantoic membrane of
the developing rat embryo [11,28] showed that the supernatant
obtained from HMEC-1 stimulated by shear stress elicited an
angiogenic effect in comparison to control (Figure 1.A). Gesta-
tional day 9.5 rat embryos were cultured for 48 h. This time
period during embryogenesis covers a major part of organogenesis,
when a complex vasculature is developed in the yolk sac as well as
in the embryo itself. The most prominent blood vessels are located
in the yolk sac surrounding the embryo. In the negative control
cultivated with HBSS and bovine serum (Figure 1.A.I), the yolk
sac exhibited an immature vascular network consisting of
irregularly organised small vessels. The corresponding vascular
system is developed by angiogenic factors like VEGF as positive
control (Figure 1.A.II). By contrast, the primitive placenta and
yolk sac of the embryos exposed to the secretome of endothelial
cells showed a highly organized vasculature containing large and
small vessels (Figure 1.A.III). Furthermore, the supernatant from
endothelial cells were treated with immobilised alkaline phospha-
tase, which metabolises mono- but not dinucleoside polypho-
sphates. Incubation with the immobilised alkaline phosphatase had
a slightly diminished effect on angiogenesis (Figure 1.A.IV). This
effect was abolished in the presence of the unspecific P2-receptor
antagonist suramin (Figure 1.A.V).
These experiments helped to choose the additional purification
steps applied to endothelial cell supernatants. First, we deprotein-
ized supernatants from stimulated endothelial cells to isolate
fractions most likely containing endothelial-derived nucleotides.
After deproteination, we desalted the supernatants by using a
preparative reversed-phase chromatography chromatography
(Figure S1.A.). The 30% acetonitrile eluates of the reversed
phase chromatography were fractionated by using a phenylbor-
onate affinity column in order to separate mononucleotides from
nucleotides containing at least two pairs of neighbouring cis-diol
Figure 1. (A) Angiogenic effects of endothelial secretome in the rat
embryo chorioallantoic membrane. The primitive placenta and yolk sac
of rat embryos cultured during organogenesis under negative control
conditions (HBSS and bovine serum) (I). The corresponding vascular
system is underdeveloped and could be improved by angiogenic
factors like VEGF as positive control (II). More complex and structured
blood vessels and red staining caused by red blood cells in the blood
vessels (marked by arrows). Morphologic evaluation of angiogenic
effect of the endothelial secretome (III), of the endothelial secretome
after incubation with alkaline phosphate (IV), and of the endothelial
secretome after incubation with alkaline phosphate in the presence of
suramin (V). (B) MALDI-TOF-TOF mass spectrum of the fraction from the
analytical reversed-phase chromatography. (C) Enhanced vascularisa-
tion of rat embryonic yolk sac membranes induced by increasing Up4U
concentrations after 48 h of culture. Typical result out of 5 similar
experiments. (D) Effect of increasing Up4U concentration on prolifer-
ation rate of human endothelial cells (n = 7). (E) Reversed phase
chromatography of the fraction of human plasma containing the
remaining nucleotides after exclusion of mononucleotides. (F) Up4U
release of cultivated endothelial cells after stimulation by a cone-and-
plate viscometer with shear stress of 3 N m-2 (n = 11).
doi:10.1371/journal.pone.0068575.g001
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groups (Figure S1.B.). Afterwards, we fractionated the nucleo-
tides containing at least two pairs of neighbouring cis-diol groups
by analytical reversed-phase chromatography. The resulting
chromatogram showed a single sharp UV peak (Figure S1.C.).
The MALDI-TOF-TOF mass spectrum obtained from the
underlying fraction revealed a molecular mass of 791.4 Da
(M+H+). Figure 1.B demonstrates the MALDI-TOF-TOF-MS/
MS-LIFT-fragmentation mass-spectrum of the underlying sub-
stance. Each mass-fragments signal was attributable to a fragment
of Up4U by using an in-house database and was identical with the
MS/MS fragmentation mass-spectrum of synthetic Up4U as
shown in Table 1, suggesting that Up4U was the substance
under investigation. Molecular structure of Up4U is given in
Figure S1.D.
After identification and synthesis of Up4U, the angiogenic
effects of synthetic Up4U were verified using the assay whole
embryo culture system [11,28]. Figure 1.C demonstrates the
impact of Up4U on the morphological pattern of the vascularisa-
tion of the yolk sac membrane. In the negative control, the yolk sac
exhibited an immature vascular network consisting of irregular
organised small vessels. By contrast, the yolk sac of the embryos
exposed to the Up4U showed a highly organized vasculature
containing large and small vessels (Figure 1.C).
Since proliferation of endothelial cells is essential for angiogen-
esis, next, the effect of Up4U on the proliferation rate of
endothelial cells was analysed. Up4U induced a strong concentra-
tion-dependent stimulation of the proliferation of human endo-
thelial cells at low concentrations; the proliferative effect of Up4U
is inhibited by a feedback mechanism at concentrations above
1027 mol L-1 (Figure 1.D). The threshold effect of Up4U was
obtained at a concentration of 1 nmol L-1.
To investigate whether Up4U plasma concentrations are
sufficient to induced angiogenesis, we quantified Up4U plasma
concentration in healthy subjects by reversed-phase chromatogra-
phy (Figure 1.E). The mean age of the subjects (m/f: 3/3) was
31.862.8, systolic blood pressure 11862 (mmHg), diastolic blood
pressure 7363 (mmHg)(each mean 6 SEM). The mean (6 SEM)
peripheral venous plasma Up4U concentration was
1.3460.26 nmol L-1 (N= 6).
Afterwards, we studied endothelial Up4U release under
physiologic conditions using a cone-and-plate viscometer. Shear
stress of 3 N m-2 for 24 h caused a strong increase in Up4U
concentration in the endothelial secretome compared to control
situation without shear stress application (Figure 1.F).
To investigate whether Up4U not only increases the prolifer-
ation rate of endothelial cells, but also effects growth of vascular
smooth muscle cells (VSMC), next the effect of Up4U on the
VSMC proliferation rate was tested in the presence and absence of
platelet-derived growth factor (PDGF). While Up4U had no direct
effect on the VSMC proliferation rate at concentration below
10 mmol L-1 (Figure 2.A), Up4U strongly increased VSMC
proliferation rate in the presence of PDGF at low concentration
range (Figure 2.B). Up4U, but not its metabolites, UTP and
UDP, caused this increasing effect, since UTP (Figure 2.C) and
UDP (Figure 2.D) had no effect on the VSMC proliferation rate
in the presence of PDGF. In the next step, we investigated
potential receptors involved. Suramin significantly inhibited Up4U
induced proliferation whereas PPADS, RBII and MRS2179 had
Table 1. Molecular masses of Up4U fragments obtained by MALDI-TOF-TOF mass spectrometry (Figure 1.B).
Fragment ions
[M+H]+
Up4U isolated from
endothelial secretome
(measured)
Up4U isolated from
plasma (measured)
Up4U fragment
mass (calculated)
synthetic Up4U
(measured)
U-NH 96.3 96.0 96.0
C4H6O3 102.4 101.8 102.0 102.1
U+CHO 140.4 140.7 140.0 140.0
C5H12O5P 184.3 184.6 183.0 184.1
U 245.3 243.7 243.1 244.0
U+H2O 261.4 261.6 261.1 261.4
U-2 H2O 207.3 207.4 207.1 207.0
Up1 325.5 324.3 323.0 325.1
Up2-H2O 384.3 385.9 384.9 385.0
Up2 402.9 403.1 402.9 403.1
Up2+H2O 419.5 419.1 420.9 421.1
Up3-H2O 465.5 465.9 464.9 467.0
Up3 483.5 484.0 482.9 484.0
Up4 561.6 567.3 562.9 563.0
M- Up4 229.3 228.4 227.1 227.0
M-U-H2O 663.4 660.9 660.9 661.2
M–H2O 773.1 773.3 772.3 773.5
M-H2O–2 H 769.3 769.4 769.9 768.5
M 791.1 791.0 791.3 791.4
The first column shows the fragment masses measured by MALDI-TOF-TOF mass spectrometry; second column shows the fragments mass of Up4U isolated from the
endothelial secretome; the third column the fragments mass of Up4U isolated from plasma; the fourth column shows the fragment masses calculated from their
respective structures; the fifth column shows the fragments masses of synthesised Up4U. M
+ = protonated parent ion; U = uracil; U = uridine; p = phosphate group, e.g.
Up3 = UTP; w/o = without.
doi:10.1371/journal.pone.0068575.t001
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no effect. From the inhibitory pattern of these non-selective P2Y-
receptor antagonists, we had the idea of the P2Y2 receptor
activated by Up4U. The non-hydrolizable ATP-cS is a selective
agonist at the P2Y2 receptor. ATPcS is also able to induce a
potent proliferation which is in part inhibitable by suramin
(Figure 2E).
Since migration of endothelial cells is essential for neovascular-
ization as well as proliferation, the effect of Up4U on migration
rate was then analysed. Up4U induced a concentration-dependent
increase in the migration rate of endothelial cells (open bars of
Figure 3.A), which was abolished in the presence of suramin,
indicating the involvement of the P2Y2-receptors in this effect
(filled bar of Figure 3A). The Up4U effect on migration rate was
stronger than the effects of UTP (Figure 3.B) and ATP
(Figure 3.C).
To investigate whether Up4U affects the ability of endothelial
cells to form capillary-like tubes, endothelial cells were exposed to
Up4U for 6 h and examined for tube formation microscopically.
Up4U produced an increased number of tubes compared to
control (Figure 3.D). The tube formation by Up4U was additive
to that of PDGF (Figure 3.D). Characteristic microscopic images
are given in Figure 3.E.
To further analyze the effects of Up4U on endothelial functions
and responsiveness, we performed experiments in gel angiogenesis
with EC spheroids. Spheroids were embedded in collagen gels and
stimulated with Up4U or VEGF as positive control. The
cumulative length of outgrowing capillary-like sprouts was
quantified after 24 h. Up4U acts as a potent inducer of sprouting
angiogenesis originating from gel-embedded EC spheroids
(Figure 3.F).
We were interested to elucidate by which intracellular pathway
Up4U can mediate proliferation. We tested potential activation of
Mapkinases and can show that in a time-dependent way Up4U
activates p38, MEK1, ERK1/2 and Akt with a maximal
stimulation after 10 min (Figure 4.A). In the presence of
U0126 (MEK1-inhibitor), SB202190 (p38 inhibitor), PD98059
(Erk1/2 inhibitor), and GSK690693 (Akt-inhibitor), Up4U
induced proliferation was significantly reduced, indicating that
all mapkinase activation is involved in the proliferative response
(Figure 4.B).
Finally, the in-vivo/ex-vivo ability of endothelial cells to release
Up4U was assessed in freshly isolated rat aortic rings (Figure 4.C).
Up4U was detected in the 24 h conditioned media of freshly
isolated aortic rings and in a subsequent 45 min. control
conditioned media. Up4U content further increased following
stimulation with either calcium ionophore (A23187) or endothelin
1.
Discussion
Up4U is a potent angiogenic factor in human vascular
endothelial cells. We tested the actions of Up4U on three major
mechanisms contributing to angiogenesis, namely migration,
proliferation, and tube formation [29]. Up4U directly increased
the proliferation rate of endothelial cells, stimulated migration and
tube formation, sprouting of endothelial cells and potentiated the
proliferative effects of a peptidic growth factor, PDGF on vascular
smooth muscle cell proliferation. Migration is only stimulated with
higher Up4U concentrations, which are not present in the plasma
of healthy humans, but may be reached locally upon release of
Up4U into the extracellular space. In order to asses the in vivo
relevance of these findings, Up4U was assayed in the supernatants
of freshly isolated aortic rings. Aortic rings released Up4U into the
supernatant under non-stimulated conditions and known inducers
of Up4U release further increased the Up4U content in
conditioned media.
Up4U belongs to the group of dinucleoside polyphosphates,
which regulates vascular tone [15], vascular smooth muscle
proliferation [30–32], platelet aggregation [33] and mesangial cell
proliferation [34]. Up4U is the first member of family of a
dinucleoside polyphosphates which has only pyrimidine-contain-
ing nucleosides at both ends. Dinucleoside polyphosphates were
isolated from body fluids and cells like platelets [35,36], brain [37],
heart [38], plasma [39] or endothelial cells [15]. Dinucleoside
polyphosphates are released into the circulation from several cell
types, including activated platelets [36,40,41], chromaffin cells of
the adrenal glands [37,42–44], tubular cells [32,45] or from
synaptic vesicles [46]. Furthermore, dinucleoside polyphosphates
are important neurotransmitter molecules in the nervous system
[47]. Dinucleoside polyphosphates occur in human plasma at
concentrations sufficient to cause vasoregulatory effects [39],
which are significantly increased in pathophysiological conditions,
like hypertension [48]. The very last one was Up4A which acts as
potent endothelium derived contracting factor [15]. The actions of
the currently known dinucleoside polyphosphates have been
extensively reviewed recently [49].
Figure 2. (A)Effect of increasing Up4U concentrations on proliferation
rate of vascular smooth muscle cells in the absence of PDGF (n = 6).
(B)Effect of increasing Up4U concentrations on proliferation rate of
vascular smooth muscle cells in the presence of PDGF (1026 mol L-1
PDGF each; n = 3). (C)Effect of increasing UTP concentrations on
proliferation rate of vascular smooth muscle cells in the presence of
PDGF (1026 mol L-1 PDGF each; n = 3). (D)Effect of increasing UDP
concentrations on proliferation rate of vascular smooth muscle cells in
the presence of PDGF (1026 mol L-1 PDGF each; n = 3). (E)Effect of Up4U
(1027 mol L-1) or ATPcS (1027 mol L-1) in the presence of PDGF
(1026 mol L-1 PDGF each; n = 3) and suramin (1024 mol L-1), PPADS
(1025 mol L-1), MRS2179 (1025 mol L-1) or RBII (1025 mol L-1) on
proliferation rate of vascular smooth muscle cells.
doi:10.1371/journal.pone.0068575.g002
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Recently the vascular endothelial growth factor receptor 2
(VEGFR2) was described as capable of synthesizing the dinucleo-
side polyphosphates uridine adenosine tetraphosphate (Up4A),
diadenosine polyphosphates (ApxA; with x= 2–6), adenosine
guanosine polyphosphates (ApxG; with x= 2–6) as well as
diguanosine polyphosphates (GpxG; with x= 2–6) [50]. Therefore,
it is likely that Up4U is synthesized by the VEGFR2 in-vivo, too.
Which receptors mediate the Up4U effects? Endothelial cells
migration is significantly inhibited by suramin. From the P2Y
receptors expressed in endothelial cells, suramin inhibits the P2Y1,
P2Y2 and P2Y6, but not the P2Y4 subtype [51]. Suramin
markedly inhibits migration in our experiments. On the other
hand RB2, which is known to block both P2Y1 and P2Y6
receptors [51], did not show a significant effect. Therefore, the
P2Y2 receptor appears to be the subtype involved in the
stimulatory effects of Up4U on endothelial cells migration. The
non-significant effect of PPADS, which is an inhibitor of P2Y1
receptors [51], is also compatible with this view. ATPcS is a
selective activator of P2Y2 receptors and can mimic the effect of
Up4U on proliferation. Up4U induced proliferation is intracellu-
larly mediated by Mapkinase activation.
In contrast to VEGF and adenosine, which are produced by a
multitude of tissues primarily as a response to hypoxia [52,53],
Up4U seems to be produced mainly by endothelial cells in an
autocrine fashion. Moreover, the experiments using shear stress
suggest that hemodynamic rather than metabolic factors regulate
Up4U secretion. Thus with respect to production and regulation,
Figure 3. (A)Effect of increasing Up4U concentrations on migration rate of endothelial cells in the absence (open bar) and presence (filled bar) of
suramin (n = 6). (B)Effect of increasing UTP concentrations on migration rate of endothelial cells (n = 3). (C)Effect of increasing ATP concentrations on
migration rate of endothelial cells (n = 3). (D) Effect of increasing Up4U concentrations on tube-formation rate of endothelial cells (5 10
25 mol L-1
Up4U and 10
27 mol L-1 PDGF as indicated in the figure; n = 12). (E)Effect of Up4U on phenotype of endothelial cells. Representative microscopic
images of endothelial cell were exposed to (a) control conditions, (b) PDGF, (c) Up4U, and (d) PDGF and Up4U for 6 h incubation time (5 10
25 mol L-1
Up4U and 10
27 mol L-1 PDGF (10ng ml-1)). (F)Quantification of 3-dimensional in vitro angiogenesis with collagen gel-embedded spheroids of EC.
Spheroids were embedded into collagen gels with Up4U and with or without VEGF. The cumulative length of all the sprouts originating from an
individual spheroid was quantified after 24 h by semiautomatic image analysis.
doi:10.1371/journal.pone.0068575.g003
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Up4U differs from the most important known peptidic and non-
peptidic angiogenic factors.
It would appear that Up4U acts synergistically with peptidic
growth factors. Up4U stimulates vascular smooth muscle cell
proliferation only when applied in combination with a peptidic
growth factor like PDGF, but this costimulatory effect is even
present with nanomolar concentrations, which are also found in
human plasma.
To what extent are the angiogenic effects of Up4U different
from those of the nucleotides known to affect angiogenesis like
ATP and UTP? Our experiments show that both ATP and UTP
do not stimulate VSMC cells growth, either alone or in
combination with PDGF. Both ATP and UTP stimulate
migration, but the effects are markedly less than that of Up4U.
Therefore, although UTP could be generated as a split product of
Up4U, it seems unlikely that Up4U exerts its effects by split
products such as UTP. Additionally, Up4U effects sprouting effects
of endothelial cells.
What is the role of Up4U-induced angiogenesis in the context of
other angiogenic factors? Up4U is secreted from endothelial cells
upon stimulation by shear stress. This mechanism of release
suggests that Up4U may mediate angiogenic stimuli from vascular
endothelial cells. On the other hand, adenosine is known to
mediate hypoxia-induced angiogenesis [54]. Also VEGF is
secreted mainly as a response to hypoxia [55]. Up4U may be
regarded as a further angiogenic factor secreted upon other stimuli
than the known angiogenic factors and possibly modulating their
actions.
In summary Up4U is a novel human endothelium-derived
angiogenic nucleotide, which acts on human endothelial cell
migration, proliferation, tube formation and induce sprouting of
endothelial cells. With respect to VSMC proliferation Up4U acts
synergistically with peptidic growth factors. These autocrine
angiogenic effects of Up4U are mainly regulated by stimulation
of EC.
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Figure S1 (A) Reversed phase chromatography of deproteinized
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